Investors
MD Medical Group Today
Investment Case
01
02
03
04
05
Revenue
Rub27.6 bn
for 2023
EBITDA
Rub9.2 bn
for 2023
Profit
up to 100%
may be allocated to dividends
Net cash position
Rub9 bn
as at 31.12.2023
Key Financials
| 2023 | 2022 | 2021 | 2020 | 2019 | |
| Revenue, Rub mln | 27,631 | 25,222 | 25,220 | 19,133 | 16,160 |
| EBITDA, Rub mln | 9,218 | 7,924 | 8,276 | 6,008 | 4,635 |
| EBITDA margin, % | 33 | 31 | 33 | 31 | 29 |
| Net profit, Rub mln | 7,823 | 6,005* | 6,143 | 4,333 | 2,787 |
| Net margin, % | 28 | 24 | 24 | 23 | 17 |
| CAPEX, Rub mln | 3,580 | 1,169 | 3,790 | 3,904 | 3,992 |
| Net debt/EBITDA | -1.0x | -0.5x | 0.2x | 0.5x | 0.8x |
*Adjusted for non-cash items
Annual reports
MD Medical Group Annual Report
PDF
2023
MD Medical Group Annual Report
PDF
2022
MD Medical Group Annual Report
PDF
2021
Share capital structure
Financial and Operating Results
1Q 2024 Operating Results
PDF
0.3 Mb
1H 2024 Financial Results
PDF
0.3 Mb
2Q 2024 Operating Results
PDF
0.3 Mb
Corporate Governance
MD Medical adheres to the highest standards of corporate governance. The Company has an effective system of corporate governance and internal control of financial and economic activities that complies with Russian legislation, the rules of the Moscow Exchange, and the best international practices.
Continuous improvement of the corporate governance system is one of the main long-term strategic priorities of the Company.
More
Events Calendar
November
16
Participation in Profit Conference in Moscow
October
30
3Q 2024 Operating results
